Micro-Particle Curcumin for the Treatment of Chronic Kidney Disease

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 518 participants.

Also called NCT02369549

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 518 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02369549
Other papers using this trial's data
  • The effect of micro-particle curcumin on chronic kidney disease progression: the MPAC-CKD randomized clinical trial Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2023-09-29 DOI, PubMed 36849161, PMC10539205 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Canada (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02369549. Randomized; quadruple masking; primary purpose prevention. Start 2015-09 (actual); primary completion 2019-11 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Micro-Particle Curcumin for the Treatment of Chronic Kidney Disease
Acronym
MPAC-CKD
Intervention (Drug)
Micro-particle Curcumin
Intervention (Drug)
Placebo
Lead sponsor
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (class: other)
Collaborator
The Kidney Foundation of Canada (class: other)
Collaborator
Canadian Institutes of Health Research (CIHR) (class: other government)

Record details

Record id
cardio:ct-nct02369549
Content hash
2fd570050375e22c0bb309a853d2f8e757445d2a1ba9eceb01201d0831be0a33